KalVista (KALV) Pharmaceuticals announced that the Ministry of Health, Labor and Welfare in Japan has granted marketing and manufacturing approval for Ekterly, a novel plasma kallikrein inhibitor, for the treatment of acute attacks of hereditary angioedema in adults and adolescents aged 12 years and older. Ekterly is the first and only oral on-demand treatment for HAE approved in Japan. Ekterly will be commercialized in Japan by KalVista’s partner, Kaken Pharmaceutical Co., Ltd. Kaken will launch Ekterly shortly after it is listed on the Japanese National Health Insurance System.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KALV:
- Promising Launch of KalVista’s Ekterly Drives Buy Rating Amid Positive Market Dynamics
- Pharvaris price target raised to $50 from $44 at Oppenheimer
- KalVista Pharmaceuticals: Strategic Market Position and Strong Buy Recommendation
- Positive Outlook for KalVista Pharmaceuticals Amid Competitive Developments and Market Growth Potential
- KalVista Pharmaceuticals: Strong Market Position and Promising Future with Ekterly Leading the Way